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TO THE EDITOR
Mastocytosis is a benign tumor with
tumor cells usually located in the skin
and/or bone marrow. It is often caused
by a spontaneous mutation in the exon
17 (D816V) of the c-kit gene, which has
been included in the 2007 WHO clas-
sification system of mastocytosis (Valent
et al., 2007 #5458). Inherited forms of
mastocytosis are rare.
Eight members of a single family
presented to a private allergy outpatient
clinic with a history of flushing and
vertigo owing to unspecific triggers,
such as physical exercise or showering.
Four of them (Figure 1) had brown-
yellowish papules that responded with
a wheal-and-flare reaction to mechan-
ical triggers (positive Darier’s sign). The
serum tryptase levels in all family mem-
bers were far in the normal range
(oo11.4mg dl 1, compared in the
Supplementary Table S1 online). The
presenting family members were two
sisters and one brother (Figure 1: indivi-
duals III2, III6, and III4). All of them had
symptomatic children as well (IV1, IV2,
IV5, and IV6). Patient IV1 was the most
severely affected individual, with attacks
of severe genital angioedema up to
twice a week. Skin punch biopsies from
patient III6 and her niece IV1 affirmed
the clinical diagnosis cutaneous masto-
cytosis (CM) (Figure 2a) with a condition
suspicious of mast cell activation syn-
drome (sMCAS, (Hamilton et al., 2011
#5461; Valent et al., 2012 #9305))
consisting in episodes of severe hypo-
tension, flushes, and angioedema. The
patients were diagnosed as suffering
from CM with sMCAS.
A more detailed analysis of the
family’s pedigree revealed that more
ancestors also suffered from a sMCAS
with episodes of flushing, fainting, and/
or diarrhea (I1 and II2 in Figure 1), all of
whom responded well to symptomatic
therapy with H1-antihistamines. The
mother (II2) and the grandfather (I1) both
reported having suffered from brownish
papules in their youth that had sponta-
neously dissolved when they had
reached their 30s. Nevertheless, they
occasionally still suffered from sMCAS
owing to unspecific triggers such as cold
water. Examinations in all patients,
including bone marrow examinations
in patient III6 and her brother III4, did
not reveal any organ infestation.
Familial mastocytosis is a rare condi-
tion and only a few families have been
described so far (Valent et al., 2007
#5458). Multiple mutations in the
c-KIT gene associated with mast cell
disorders have been described so far
(Bodemer et al., 2010 #8513;
Molderings et al., 2010 #5411; Wasag
et al., 2011 #8310). The most prominent
is the D816V mutation (Valent et al.,
2007 #5458). Sequencing the c-KIT
gene by PCR in the skin biopsies from
patients III6 and her niece IV1 (Figures 1
and 2b) showed a mutation in exon 18
at position 849 (S849I), which, to our
knowledge, is previously unreported. A
second mutation in exon 18 at position
835 (c-Kit M835K) was found exclu-
sively in the most severely affected
patient IV1. The mutations could be
identified in material derived from skin
biopsies but not in blood samples or
buccal mouth swabs from our patients
Abbreviations: CM, cutaneous mastocytosis; FFPE, formalin-fixed paraffin-embedded; sMCAS, suspected
mast cell activation syndrome
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and all other family members. This could
be explained by somatic mutations of
the c-Kit gene, indicating mosaicism. An
elevated frequency of somatic mutations
in other hematological malignancies has
already been observed in the Jak 2 locus
(Campbell, 2009 #8516). However,
technical insufficiencies might have
resulted in an insufficient sensitivity of
the 11 PCRs from the peripheral blood
and the 18 PCRs from the mucosal
mouth swabs. Taking into account this
shortcoming, we might have overlooked
a true, inherited germ-line mutation at
position S849i.
The c-kit gene is located on chromo-
some 4 q11–12. By analyzing the clinical
symptoms of members of the four genera-
tions of the concerned family, we assume
that the c-KIT S849i mutation contri-
butes to a rather benign phenotype of
CM gradually, nevertheless incompletely
resolving by age. The severe, relapsing
genital angioedema of patient IV1 is a
rather untypical feature of the mast cell
activation syndrome (Hamilton et al.,
2011 #5461). Hereditary angioedema as
a differential diagnosis was ruled out
by repeated, normal C4, C3c, and C1
esterase inhibitor measurements and
by the good clinical response to the
quadruple dose of nonsedating oral anti-
histamine used as a standard treatment of
chronic, spontaneous urticaria/angio-
edema (Zuberbier et al., 2009 #1110;
Valent et al., 2012 #9305). Nevertheless,
we think that the angioedema in this
patient more probably was a grade I
anaphylaxis and, consequently, part of
the sMCAS than a presentation of a
second disease, chronic spontaneous
angioedema. Overall, this family with a
non-D816V mutation suffered from an
early onset and a rather benign further
course of the disease.
c-kit mutations can be detected in up to
90% of patients with mastocytosis
(Teodosio et al., 2010 #8510), about
50% are various mutations in c-kit exon
17 in adults (Lanternier et al., 2008
#8511) and around 40% in children
(Bodemer et al., 2010 #8513). The S849i
mutation in the family described herein
lies on exon 18 but is situated in proximity
to the most commonly identified mutation
in CM at codon 816 (D816V). The locali-
zation in the tyrosine kinase domain
region 2 (similar to the most common
mutations) in the 11th b sheet structure
(Laine et al., 2011 #5410) suggests that
this mutation may lead to functional
alterations in the tyrosine receptor kinase
activity of the c-kit molecule. Interestingly,
in patients with CM, a mutation at posi-
tion 839 (E839K, exon 18) has also been
described (Laine et al., 2011 #5410).
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Figure 1. The family’s pedigree. Sequencing demonstrated the novel c-KIT mutation in patient III6 and IV1.
a
b
Figure 2. Histology and mutations in c-Kit exon 18. (a) Clinical picture and histology of the skin biopsy
of patient IV1 suffering from cutaneous mastocytosis (CM). The overview and close-up depict numerous
mast cells (H/E and Giemsa stains), consistent with the diagnosis of CM. The magnified inserts show
mast cells. (b) Sequence of c-kit exon 18 identified two mutations. Mutation 1: AAG instead of ATG
leading to an exchange from methionine (M) to lysine (K) at amino-acid position 835 (c-Kit M835K).
Mutation 2: ATT instead of AGT leading to a change from serine (S) to isoleucine (I) at position 849
(c-Kit S849I).
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Summing up, we present a previously
unreported mutation in exon 18 of the
c-KIT gene, contributing to a phenotype
of CM with sMCAS and a tendency
to incomplete resolution in adulthood.
We also identified an additional muta-
tion in exon 18 of the c-KIT gene
possibly associated with a more severe
phenotype.
The study has been approved by the
institutional ethics committee (Ethics
committee of the Medical University of
Vienna, approval number 901/2009).
Informed written consent was given by
all patients and their parents, respec-
tively. The study adhered to the
Declaration of Helsinki principles.
DNA from formalin-fixed paraffin-
embedded (FFPE) skin biopsies were
extracted using the DNAeasy Blood
and Tissue Kit (Qiagen, Valencia, CA)
after deparaffinization. For DNA extrac-
tion from blood, 200ml of blood was
used with the Qiagen DNA Blood and
Tissue Kit according to the manufac-
turer’s instructions. To examine c-Kit
exons 8, 9, 11, 13, 17, and 18 for
mutations in CM samples, FFPE-derived
DNA was further amplified using nested
PCR with a multiplex preamplification
step to compensate for limited DNA
yields from FFPE extraction. Preamplifica-
tion was performed in a 25-ml volume
with the Ampli Taq Gold 360 DNA Poly-
merase Kit (Applied Biosystems, Vienna,
Austria) and at least 25ng of DNA tem-
plate. As a second step, amplification
using nested primer pairs (see online
repository for table) was performed with
the Ampli Taq Gold 360 DNA Polymer-
ase Kit and 1ml of the preamplification
product. For amplification steps for blood-
derived DNA, the same protocol and
primers were used as for FFPE material.
After PCR amplification, appropriate exon
lengths were controlled on a 1.5% agar-
ose gel, and PCR products were subse-
quently sequenced using an ABI 3000
capillary sequencer (Applied Biosystems).
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TO THE EDITOR
In the past few years, intravital imaging
has been developing, especially that
using a multiphoton confocal technique
(Li et al., 2012). Such a technique is quite
a useful tool for understanding cellular or
molecular dynamic events in vivo. How-
ever, this technique requires labeling of
fluorescence, and the fluorescence is
usually labeled genetically, by trans-
fection, or by direct linking. In the case
of human cells, there is the concern that
these treatments affect the functional
capability of the treated cells. A method
of intravital imaging that does not have
biological influences is needed.
Recently, we developed a far-red
luminescent probe as a convenient
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